Vivek Subbiah is an internationally recognized leader in tumor-agnostic precision oncology, medical oncologist at SCRI Oncology Partners and Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (SCRI). He leads SCRI’s early-phase oncology strategy across a national network of drug development units, expanding access to first-in-human and precision oncology trials. Prior to joining SCRI, he spent nearly 15 years at MD Anderson Cancer Center, where he held senior leadership roles within the Phase I program and cancer medicine research.
Dr. Subbiah has served as principal investigator on more than 100 phase I/II trials and as co-investigator on over 200 clinical studies, including practice-changing trials that led to multiple FDA and EMA approvals, notably for BRAF and RET tissue-agnostic therapies. His research spans endocrine cancers, sarcoma, targeted therapy, and immunotherapy. In recognition of his leadership in oncology communication and advocacy, he was awarded the Yvonne Award in the Voice of Oncology category in 2024.
The 100 Most Influential People in Oncology in 2025 recognizes the changemakers in cancer care who have helped shape current practice in oncology and continue to drive innovation and research towards better outcomes, advocacy, philanthropy, leadership and education. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential People in Oncology in 2025 and stay tuned for the results of special category nominations to be announced.
